Dr. Ramalingam on Pemetrexed and Bevacizumab as Maintenance Therapy for Advanced NSCLC

June 11, 2019
Suresh S. Ramalingam, MD

Cancer Network spoke with Suresh S. Ramalingam, MD, of Emory University, about pemetrexed, bevacizumab, or both for advanced non-squamous NSCLC.

Cancer Network spoke with Suresh S. Ramalingam, MD, professor of hematology/oncology and the deputy director of Winship Cancer Institute, Emory University, about the results of the ECOG-ACRIN 5508 trial (abstract 9002). The study focused on pemetrexed, bevacizumab, or a combination of both as maintenance therapy for advanced non-squamous NSCLC, and the findings were presented at ASCO 2019.

Related Content:

ASCO Lung Cancer | Lung Cancer